Brain Pericytes As Mediators of Neuroinflammation

Trends in Pharmacological Sciences

Volumn 38, Issue 3, 2017, Pages 291-304

  Rustenhoven, Justin ^a   Jansson, Deidre ^a   Smyth, Leon C ^a   Dragunow, Mike ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

blood brain barrier; drug therapy; neurodegeneration

Indexed keywords

CELL ADHESION MOLECULE; CELL ANTIGEN; CELL RECEPTOR; CHEMOKINE; CYTOKINE; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; BLOOD BRAIN BARRIER; BRAIN PERICYTE; CELL FUNCTION; COCULTURE; ENDOCYTOSIS; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LEUKOCYTE; MEDIATOR RELEASE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARENCHYMA CELL; POLARIZATION; REVIEW; SPECIES DIFFERENCE; ANIMAL; BRAIN; ENCEPHALITIS; IMMUNOLOGY; PATHOLOGY; PERICYTE;

ANIMALS; BRAIN; ENCEPHALITIS; HUMANS; PERICYTES;

EID: 85010736824     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.12.001     Document Type: Review

References (116)

1. 1 Winkler, E.A., et al. Central nervous system pericytes in health and disease. Nat. Neurosci. 14 (2011), 1398–1405.
2. 2 Winkler, E.A., et al. The pericyte: a forgotten cell type with important implications for Alzheimer's disease?. Brain Pathol. 24 (2014), 371–386.
3. 3 de Souza, L.E., et al. Mesenchymal stem cells and pericytes: to what extent are they related?. Stem Cells Dev., 2016, 10.1089/scd.2016.0109 Published online November 3, 2016.
4. 4 Attwell, D., et al. What is a pericyte?. J. Cereb. Blood Flow Metab., 2015, 10.1177/0271678X15610340 Published online September 10, 2015.
5. 5 Armulik, A., et al. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21 (2011), 193–215.
6. 6 Park, T.I., et al. Cultured pericytes from human brain show phenotypic and functional differences associated with differential CD90 expression. Sci. Rep., 6, 2016, 26587.
7. 7 Armulik, A., et al. Pericytes regulate the blood–brain barrier. Nature 468 (2010), 557–561.
8. 8 Guijarro-Munoz, I., et al. Lipopolysaccharide activates TLR4-mediated NF-κB signaling pathway and proinflammatory response in human pericytes. J. Biol. Chem. 289 (2014), 2457–2468.
9. 9 Pieper, C., et al. Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro. Brain Res. 1550 (2014), 1–8.
10. 10 Pieper, C., et al. Pericytes support neutrophil transmigration via interleukin-8 across a porcine co-culture model of the blood–brain barrier. Brain Res. 1524 (2013), 1–11.
11. 11 Rustenhoven, J., et al. An anti-inflammatory role for C/EBPδ in human brain pericytes. Sci. Rep., 5, 2015, 12132.
12. 12 Jansson, D., et al. A role for human brain pericytes in neuroinflammation. J. Neuroinflammation, 11, 2014, 104.
13. 13 Rustenhoven, J., et al. TGF-β1 regulates human brain pericyte inflammatory processes involved in neurovasculature function. J. Neuroinflammation 13 (2016), 1–15.
14. 14 Matsumoto, J., et al. Tumor necrosis factor-alpha-stimulated brain pericytes possess a unique cytokine and chemokine release profile and enhance microglial activation. Neurosci. Lett. 578 (2014), 133–138.
15. 15 Kovac, A., et al. Brain microvascular pericytes are immunoactive in culture: cytokine, chemokine, nitric oxide, and LRP-1 expression in response to lipopolysaccharide. J. Neuroinflammation, 8, 2011, 139.
16. 16 Smith, A.M., et al. Adult human glia, pericytes and meningeal fibroblasts respond similarly to IFNy but not to TGFβ1 or M-CSF. PLoS One, 8, 2013, e80463.
17. 17 Proebstl, D., et al. Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. J. Exp. Med. 209 (2012), 1219–1234.
18. 18 Balabanov, R., et al. Role of central nervous system microvascular pericytes in activation of antigen-primed splenic T-lymphocytes. J. Neurosci. Res. 55 (1999), 578–587.
19. 19 Verbeek, M.M., et al. T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4/vascular cell adhesion molecule-1 interactions. J. Immunol. 154 (1995), 5876–5884.
20. 20 Ayres-Sander, C.E., et al. Transendothelial migration enables subsequent transmigration of neutrophils through underlying pericytes. PLoS One, 8, 2013, e60025.
21. 21 Stark, K., et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs. Nat. Immunol. 14 (2013), 41–51.
22. 22 Owens, T., et al. Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 67 (2008), 1113–1121.
23. 23 Sweeney, M.D., et al. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat. Neurosci. 19 (2016), 771–783.
24. 24 Voisin, M-B., et al. Venular basement membranes ubiquitously express matrix protein low-expression regions: characterization in multiple tissues and remodeling during inflammation. Am. J. Pathol. 176 (2010), 482–495.
25. 25 Wang, S., et al. Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. J. Exp. Med. 203 (2006), 1519–1532.
26. 26 Tigges, U., et al. TNF-α promotes cerebral pericyte remodeling in vitro, via a switch from α1 to α2 integrins. J. Neuroinflammation, 1, 2013 331–310.
27. 27 Hall, C.N., et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 508 (2014), 55–60.
28. 28 Minghetti, L., Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63 (2004), 901–910.
29. 29 Zhao, M-L., et al. Inducible nitric oxide synthase expression is selectively induced in astrocytes isolated from adult human brain. Brain Res. 813 (1998), 402–405.
30. 30 Wolburg, H., Lippoldt, A., Tight junctions of the blood–brain barrier: development, composition and regulation. Vascul. Pharmacol. 38 (2002), 323–337.
31. 31 Mann, G., et al. Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon. BBA Biomembranes 819 (1985), 241–248.
32. 32 Zlokovic, B.V., Cerebrovascular permeability to peptides: manipulations of transport systems at the blood–brain barrier. Pharm. Res. 12 (1995), 1395–1406.
33. 33 Zlokovic, B.V., et al. Kinetics of arginine-vasopressin uptake at the blood–brain barrier. BBA Biomembranes 1025 (1990), 191–198.
34. 34 Zloković, B.V., et al. Transport of leucine-enkephalin across the blood–brain barrier in the perfused guinea pig brain. J. Neurochem. 49 (1987), 310–315.
35. 35 Ransohoff, R.M., et al. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3 (2003), 569–581.
36. 36 van de Haar, H.J., et al. Blood–brain barrier leakage in patients with early Alzheimer disease. Radiology 281 (2016), 527–535.
37. 37 Zlokovic, B.V., Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12 (2011), 723–738.
38. 38 van de Haar, H.J., et al. Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging. Neurobiol. Aging 45 (2016), 190–196.
39. 39 Zipser, B., et al. Microvascular injury and blood–brain barrier leakage in Alzheimer's disease. Neurobiol. Aging 28 (2007), 977–986.
40. 40 Farkas, E., Luiten, P.G., Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64 (2001), 575–611.
41. 41 Sengillo, J.D., et al. Deficiency in mural vascular cells coincides with blood–brain barrier disruption in Alzheimer's disease. Brain Pathol. 23 (2013), 303–310.
42. 42 Montagne, A., et al. Blood–brain barrier breakdown in the aging human hippocampus. Neuron 85 (2015), 296–302.
43. 43 Halliday, M.R., et al. Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J. Cereb. Blood Flow Metab. 36 (2016), 216–227.
44. 44 Bell, R.D., et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68 (2010), 409–427.
45. 45 Davalos, D., et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat. Commun., 3, 2012, 1227.
46. 46 Ryu, J.K., et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat. Commun., 6, 2015, 8164.
47. 47 Paul, J., et al. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med. 204 (2007), 1999–2008.
48. 48 Kuroda, J., et al. Nox4 is a major source of superoxide production in human brain pericytes. J. Vasc. Res. 51 (2014), 429–438.
49. 49 Nishimura, A., et al. Detrimental role of pericyte Nox4 in the acute phase of brain ischemia. J. Cereb. Blood Flow Metab. 36 (2016), 1143–1154.
50. 50 Takata, F., et al. Brain pericytes among cells constituting the blood–brain barrier are highly sensitive to tumor necrosis factor-alpha, releasing matrix metalloproteinase-9 and migrating in vitro. J. Neuroinflammation, 8, 2011, 106.
51. 51 Takahashi, Y., et al. p38 MAP kinase mediates transforming-growth factor-1-induced upregulation of matrix metalloproteinase-9 but not -2 in human brain pericytes. Brain Res. 1593 (2014), 1–8.
52. 52 Thanabalasundaram, G., et al. Regulation of the blood–brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Res. 1347 (2010), 1–10.
53. 53 Jiang, S., et al. Vascular endothelial growth factors enhance the permeability of the mouse blood–brain barrier. PLoS One, 9, 2014, e86407.
54. 54 Bai, Y., et al. Pericytes contribute to the disruption of the cerebral endothelial barrier via increasing VEGF expression: implications for stroke. PLoS One, 10, 2015, e0124362.
55. 55 Bauer, A.T., et al. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J. Cereb. Blood Flow Metab. 30 (2010), 837–848.
56. 56 Halliday, M.R., et al. Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein E4 carriers and blood–brain barrier breakdown. JAMA Neurol. 70 (2013), 1198–1200.
57. 57 Persidsky, Y., et al. Dysfunction of brain pericytes in chronic neuroinflammation. J. Cereb. Blood Flow Metab. 36 (2015), 794–807.
58. 58 Jansson, D., et al. Interferon-γ blocks signalling through PDGFRβ in human brain pericytes. J. Neuroinflammation 13 (2016), 1–19.
59. 59 Nishioku, T., et al. Detachment of brain pericytes from the basal lamina is involved in disruption of the blood–brain barrier caused by lipopolysaccharide-induced sepsis in mice. Cell. Mol. Neurobiol. 29 (2009), 309–316.
60. 60 Jung, K-H., et al. Multipotent PDGFRβ-expressing cells in the circulation of stroke patients. Neurobiol. Dis. 41 (2011), 489–497.
61. 61 Sagare, A.P., et al. Shedding of soluble platelet-derived growth factor receptor-β from human brain pericytes. Neurosci. Lett. 607 (2015), 97–101.
62. 62 Schultz, N., et al. Involvement of matrix metalloproteinase-9 in amyloid-beta 1-42-induced shedding of the pericyte proteoglycan NG2. J. Neuropathol. Exp. Neurol. 73 (2014), 684–692.
63. 63 Kristensson, K., Olsson, Y., Accumulation of protein tracers in pericytes of the central nervous system following systemic injection in immature mice. Acta Neurol. Scand. 49 (1973), 189–194.
64. 64 Schultz, N., et al. Amylin alters human brain pericyte viability and NG2 expression. J. Cereb. Blood Flow Metab., 2016, 10.1177/0271678X16657093 Published online June 28, 2016.
65. 65 Thomas, W.E., Brain macrophages: on the role of pericytes and perivascular cells. Brain Res. Rev. 31 (1999), 42–57.
66. 66 Balabanov, R., et al. CNS microvascular pericytes express macrophage-like function, cell surface integrin alpha M, and macrophage marker ED-2. Microvasc. Res. 52 (1996), 127–142.
67. 67 Castejón, O., Submicroscopic changes of cortical capillary pericytes in human perifocal brain edema. J. Submicrosc. Cytol. 16 (1984), 601–618.
68. 68 Sagare, A.P., et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat. Commun., 4, 2013, 2932.
69. 69 Zlokovic, B.V., et al. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain. J. Neurochem. 115 (2010), 1077–1089.
70. 70 Deane, R., et al. ApoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118 (2008), 4002–4013.
71. 71 Deane, R., et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43 (2004), 333–344.
72. 72 Shibata, M., et al. Clearance of Alzheimer's amyloid-β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J. Clin. Invest. 106 (2000), 1489–1499.
73. 73 Bell, R.D., et al. SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells. Nat. Cell Biol. 11 (2009), 143–153.
74. 74 Davis-Salinas, J., Van Nostrand, W.E., Amyloid β-protein aggregation nullifies its pathologic properties in cultured cerebrovascular smooth muscle cells. J. Biol. Chem. 270 (1995), 20887–20890.
75. 75 Dorr, A., et al. Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. Brain 135 (2012), 3039–3050.
76. 76 Iliff, J.J., et al. Cerebral arterial pulsation drives paravascular CSF–interstitial fluid exchange in the murine brain. J. Neurosci. 33 (2013), 18190–18199.
77. 77 Carare, R., et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol. 34 (2008), 131–144.
78. 78 Ozen, I., et al. Brain pericytes acquire a microglial phenotype after stroke. Acta Neuropathol. 128 (2014), 381–396.
79. 79 Sakuma, R., et al. Brain pericytes serve as microglia-generating multipotent vascular stem cells following ischemic stroke. J. Neuroinflammation, 13, 2016, 1.
80. 80 Navarro, R., et al. Role of nucleotide-binding oligomerization domain 1 (NOD1) in pericyte-mediated vascular inflammation. J. Cell. Mol. Med. 20 (2016), 980–986.
81. 81 Bansal, R., et al. Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. Mol. Cancer Ther. 11 (2012), 2419–2428.
82. 82 Brown, G.C., Vilalta, A., How microglia kill neurons. Brain Res. 1628 (2015), 288–297.
83. 83 Yang, Y., et al. The PDGF-BB–SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages. Nat. Commun., 7, 2016, 11385.
84. 84 Fu, A.K., et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc. Natl Acad. Sci. U. S. A. 113 (2016), E2705–E2713.
85. 85 Cardona, A.E., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9 (2006), 917–924.
86. 86 Maier, C.L., Pober, J.S., Human placental pericytes poorly stimulate and actively regulate allogeneic CD4 T cell responses. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 183–189.
87. 87 Domev, H., et al. Immunoevasive pericytes from human pluripotent stem cells preferentially modulate induction of allogeneic regulatory T cells. Stem Cells Transl. Med. 3 (2014), 1169–1181.
88. 88 Owens, T., Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation. Eur. J. Immunol. 30 (2000), 1002–1009.
89. 89 Melgar, M.A., et al. Postischemic reperfusion: ultrastructural blood–brain barrier and hemodynamic correlative changes in an awake model of transient forebrain ischemia. Neurosurgery 56 (2005), 571–581.
90. 90 MacLeod, M.K., et al. Memory CD4 T cells: generation, reactivation and re-assignment. Immunology 130 (2010), 10–15.
91. + cells by murine brain microvessel endothelial cells and smooth muscle/pericytes. J. Immunol. 151 (1993), 38–47.
92. 92 Smith, A.M., Dragunow, M., The human side of microglia. Trends Neurosci. 37 (2014), 125–135.
93. 93 Arora, A., Bhagat, N., Insight into the molecular imaging of Alzheimer's disease. Int. J. Biomed. Imaging, 2016, 2016, 7462014.
94. 94 Jennewein, M., et al. Two-and three-dimensional co-culture models of soft tissue healing: pericyte–endothelial cell interaction. Cell Tissue Res. 365 (2016), 279–293.
95. 95 Tarallo, S., et al. Human pericyte–endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment. Acta Diabetol. 49 (2012), 141–151.
96. 96 Bersini, S., Moretti, M., 3D functional and perfusable microvascular networks for organotypic microfluidic models. J. Mater. Sci. Mater. Med., 26, 2015, 180.
97. 97 Wolak, D.J., Thorne, R.G., Diffusion of macromolecules in the brain: implications for drug delivery. Mol. Pharm. 10 (2013), 1492–1504.
98. 98 Leaf, I.A., et al. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J. Clin. Invest., 2016, 10.1172/JCI87532 Published online November 21, 2016.
99. 99 Nakagomi, T., et al. Brain vascular pericytes following ischemia have multipotential stem cell activity to differentiate into neural and vascular lineage cells. Stem Cells 33 (2015), 1962–1974.
100. 100 Buttgereit, A., et al. Sall1 is a transcriptional regulator defining microglia identity and function. Nat. Immunol. 17 (2016), 1397–1406.
101. 101 Butovsky, O., et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17 (2014), 131–143.
102. 102 Raica, M., Cimpean, A.M., Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals 3 (2010), 572–599.
103. 103 Kang, E., Shin, J.W., Pericyte-targeting drug delivery and tissue engineering. Int. J. Nanomedicine, 11, 2016, 2397.
104. 104 Padel, T., et al. Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson's disease. Neurobiol. Dis. 94 (2016), 95–105.
105. 105 Liu, R., et al. IL-17 promotes neutrophil-mediated immunity by activating microvascular pericytes and not endothelium. J. Immunol. 197 (2016), 2400–2408.
106. 106 He, L., et al. Analysis of the brain mural cell transcriptome. Sci. Rep., 6, 2016, 35108.
107. 107 Winkler, E.A., et al. Blood–spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 125 (2013), 111–120.
108. 108 Verbeek, M.M., et al. Rapid degeneration of cultured human brain pericytes by amyloid β protein. J. Neurochem. 68 (1997), 1135–1141.
109. 109 Muramatsu, R., et al. Prostacyclin prevents pericyte loss and demyelination induced by lysophosphatidylcholine in the central nervous system. J. Biol. Chem. 290 (2015), 11515–11525.
110. 110 Warmke, N., et al. Pericytes in diabetes-associated vascular disease. J. Diabetes Complications 30 (2016), 1643–1650.
111. 111 Marchi, N., Lerner-Natoli, M., Cerebrovascular remodeling and epilepsy. Neuroscientist 19 (2013), 304–312.
112. 112 Liu, S., et al. The role of pericytes in blood–brain barrier function and stroke. Curr. Pharm. Des. 18 (2012), 3653–3662.
113. 113 Zehendner, C.M., et al. Traumatic brain injury results in rapid pericyte loss followed by reactive pericytosis in the cerebral cortex. Sci. Rep., 5, 2015, 13497.
114. 114 Göritz, C., et al. A pericyte origin of spinal cord scar tissue. Science 333 (2011), 238–242.
115. 115 Ochs, K., et al. Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J. Neuroimmunol. 265 (2013), 106–116.
116. 116 Cheng, L., et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153 (2013), 139–152.